Figure 2.
Median DPP-4 inhibition after single oral doses of 5 mg linagliptin in patients with different degrees of hepatic function. Normal hepatic function (n = 8) (); Mild hepatic impairment (n = 8) (
); Moderate hepatic impairment (n = 9) (
); Severe hepatic impairment (n = 8) (
)